PTC Therapeutics Exceeds 2025 Revenue Guidance, Projects Strong 2026 Growth, Advances HD Program

summarizeSummary

PTC Therapeutics reported preliminary 2025 revenues that exceeded guidance and provided 2026 product revenue guidance indicating significant year-over-year growth, alongside positive updates for its Huntington's disease program.

check_boxKey Events

• Exceeded 2025 Revenue Guidance

  Reported preliminary total unaudited net product and royalty revenue of approximately $823.4 million for fiscal year 2025, surpassing previous guidance.

• Strong 2026 Revenue Guidance

  Anticipates full-year 2026 total product revenues of $700 million to $800 million, excluding Evrysdi royalty and collaboration revenue, representing 19-36% year-over-year growth.

• Sephience Launch Momentum

  Sephience generated approximately $112.1 million in net revenue since launch in 2025, with strong Q4 performance of $92.5 million and 946 patients on commercial therapy worldwide.

• Advancement in Huntington's Disease Program

  Reached alignment with the FDA on the design of a global Phase 3 trial for votoplam, planned for H1 2026, with the FDA open to an Accelerated Approval pathway.

auto_awesomeAnalysis

PTC Therapeutics delivered a strong financial update, with preliminary 2025 results exceeding expectations and robust revenue growth projected for 2026. The successful launch of Sephience and the significant progress in the votoplam Huntington's disease program, including FDA alignment on a Phase 3 trial and openness to accelerated approval, are key drivers for future value. The company's substantial cash reserves provide a solid foundation for continued R&D and commercialization efforts. Investors should monitor the Sephience global rollout and the initiation of the votoplam Phase 3 trial.